Efficacy and safety of Pefikan in adjuvant treatment of post-hepatitis B cirrhosis

Wang Chao-jie; Jiang Hai

doi:10.3969/j.issn.1672-8157.2024.06.014

Abstract：Objective To investigate the efficacy and safety of Pefican (Bifidobacterium triple viable capsule) in the ad-juvant treatment of post-hepatitis B cirrhosis. Methods A total of 80 patients with post-hepatitis B cirrhosis admitted to Hai'an People's Hospital from January 2020 to December 2023 were included and divided into the Entecavir group and Pe-fikan group by random number table method,with 40 in each group. The patients in the Entecavir group were treated with oral Entecavir tablets and those in the Pefican group with oral Entecavir tablets and pefican. The clinical efficacy,adverse re-actions,changes of immune indexes (CD4+,CD8+,CD4+/CD8+) and liver function indexes (serum total bilirubin (TBIL),aspar-tate aminotransferase (AST),alanine aminotransferase (ALT)) before and after treatment were compared between the two groups. Results The total effective rate was significantly higher in the Pefican group than in the Entecavir group (97.50％ vs 80.00％,P<0.05). The adverse reaction rate was 5.00％ in the Pefican group and 7.50％ in the Entecavir group,showing no statistical-ly significant difference (P>0.05). After treatment,CD4+and CD4+/CD8+were (49.65±3.85)％ and (1.72±0.26),respectively in the Pefican group,higher than those of (44.85±4.26)％ and (1.41±0.30) in the Entecavir group. The CD8+was (28.67±3.36)％,lower than that of (32.15±4.15)％ in the Entecavir group (P<0.05). The TBIL,AST and ALT levels in the Pefican group were (39.64±5.99) μmol·L-1,(42.39±3.53) U·L-1 and (39.65±4.94) U·L-1,respectively. They were lower than those of (44.29±6.23) μmol·L-1,(48.62±5.23) U·L-1,(46.23±5.11) U·L-1 in the Entecavir group (P<0.05). Conclusion The effect of Pefican in the adjuvant treatment of post-hepatitis B cirrhosis is good because it can improve the immune function and liver function. Meanwhile,its side effects are less and it is safe and reliable.